Bioventus (NASDAQ:BVS) Stock Rating Upgraded by Barrington Research

Bioventus (NASDAQ:BVS) was upgraded by research analysts at Barrington Research to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Separately, Weiss Ratings reissued a “hold (c-)” rating on shares of Bioventus in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy”.

Bioventus Trading Down 5.3%

Shares of BVS opened at $8.07 on Monday. The company’s fifty day simple moving average is $7.73 and its 200-day simple moving average is $7.29. The company has a market cap of $667.87 million, a P/E ratio of 67.26 and a beta of 0.80. The company has a current ratio of 1.74, a quick ratio of 1.14 and a debt-to-equity ratio of 1.50. Bioventus has a twelve month low of $5.81 and a twelve month high of $11.25.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.